pleconaril has been researched along with Infections, Picornaviridae in 17 studies
WIN 63843: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| " Investigational agents such as the capsid inhibitors pleconaril and pocapavir show promise for treatment of neonatal enterovirus infections, and other investigational agents are being developed." | 4.98 | Neonatal nonpolio enterovirus and parechovirus infections. ( DeBiasi, RL; Harik, N, 2018) |
| "Oral pleconaril treatment was studied in 2 parallel randomized, double-blind, placebo-controlled trials." | 2.71 | Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. ( Coats, TL; Collett, M; Cooper, EC; Hayden, FG; Herrington, DT; Hudson, S; Kim, K; Liu, S; McKinlay, M; Pevear, DC; Villano, SA, 2003) |
| "Pleconaril was generally well tolerated; the liquid formulation caused gastrointestinal disturbance in all groups (diarrhoea 10-14%, nausea 5-9%, abdominal discomfort 6-8%), and tablets were associated with a greater incidence of nausea (3% for placebo versus 7% for pleconaril, P = 0." | 2.70 | Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials. ( Blatter, MM; Coats, T; Hassman, HA; Hayden, FG; Kim, K; Liu, S; Zhang, B, 2002) |
| "Pleconaril is a novel, orally available, systemically acting molecule whose pharmacokinetics are characterized by a two-compartment open model with first-order absorption and with a safety profile similar to that of placebo." | 2.42 | Pleconaril, a novel antipicornaviral agent. ( Florea, NR; Maglio, D; Nicolau, DP, 2003) |
| "Recent attempts to develop antiviral treatments for the common cold represent a substantial advance over previous efforts." | 2.41 | The treatment of rhinovirus infections: progress and potential. ( Turner, RB, 2001) |
| "Pleconaril is an oral antiviral agent being developed by ViroPharma and Sanofi-Synthélabo (formerly Sterling Winthrop) for the potential treatment of several picornavirus-induced infections, including respiratory diseases and viral meningitis." | 2.41 | Pleconaril Sanofi Synthélabo/ViroPharma. ( Billich, A, 2000) |
| "Conversely, trials conducted in cases of upper respiratory tract infections and meningitis caused by enteroviruses have shown modest results." | 1.30 | [New antivirals for respiratory tract viruses]. ( Le Moing, V, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morley, A | 1 |
| Tomkinson, N | 1 |
| Cook, A | 1 |
| MacDonald, C | 1 |
| Weaver, R | 1 |
| King, S | 1 |
| Jenkinson, L | 1 |
| Unitt, J | 1 |
| McCrae, C | 1 |
| Phillips, T | 1 |
| Wald, J | 1 |
| Pasin, M | 1 |
| Richter, M | 1 |
| Walther, C | 1 |
| Mathai, N | 1 |
| Kirchmair, J | 1 |
| Makarov, VA | 1 |
| Goessweiner-Mohr, N | 1 |
| Marlovits, TC | 1 |
| Zanella, I | 1 |
| Real-Hohn, A | 1 |
| Verdaguer, N | 1 |
| Blaas, D | 1 |
| Schmidtke, M | 1 |
| Harik, N | 1 |
| DeBiasi, RL | 1 |
| Holmberg, R | 1 |
| Klitz, W | 1 |
| Blixt, M | 1 |
| Berggren, PO | 1 |
| Juntti-Berggren, L | 1 |
| Niklasson, B | 1 |
| Choi, HJ | 1 |
| Song, JH | 1 |
| Lim, CH | 1 |
| Baek, SH | 1 |
| Kwon, DH | 1 |
| Wildenbeest, JG | 1 |
| Harvala, H | 1 |
| Pajkrt, D | 1 |
| Wolthers, KC | 1 |
| van de Ven, AA | 1 |
| Douma, JW | 1 |
| Rademaker, C | 1 |
| van Loon, AM | 1 |
| Wensing, AM | 1 |
| Boelens, JJ | 1 |
| Sanders, EA | 1 |
| van Montfrans, JM | 1 |
| Florea, NR | 1 |
| Maglio, D | 1 |
| Nicolau, DP | 1 |
| Hayden, FG | 3 |
| Herrington, DT | 1 |
| Coats, TL | 1 |
| Kim, K | 2 |
| Cooper, EC | 1 |
| Villano, SA | 1 |
| Liu, S | 2 |
| Hudson, S | 1 |
| Pevear, DC | 1 |
| Collett, M | 1 |
| McKinlay, M | 1 |
| Fleischer, R | 1 |
| Laessig, K | 1 |
| Rogers, JM | 1 |
| Diana, GD | 1 |
| McKinlay, MA | 1 |
| Le Moing, V | 1 |
| Reina, J | 1 |
| Ballesteros, F | 1 |
| Turner, RB | 1 |
| Billich, A | 1 |
| Coats, T | 1 |
| Hassman, HA | 1 |
| Blatter, MM | 1 |
| Zhang, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Biomarkers and Clinical Characteristics That Identify the Risk of an Exacerbation Following Viral Upper Respiratory Tract Infections in COPD Patients[NCT01376830] | 35 participants (Actual) | Observational | 2011-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for pleconaril and Infections, Picornaviridae
| Article | Year |
|---|---|
Neonatal nonpolio enterovirus and parechovirus infections.
Topics: Antiviral Agents; Cross Infection; Enterovirus; Enterovirus Infections; Female; Fomites; Humans; Inf | 2018 |
The need for treatment against human parechoviruses: how, why and when?
Topics: Animals; Antiviral Agents; Central Nervous System Infections; Disease Models, Animal; Humans; Infant | 2010 |
Pleconaril, a novel antipicornaviral agent.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Area Under Curve; Biological Availability; Half-Life; Hum | 2003 |
Update on influenza and rhinovirus infections.
Topics: Acetamides; Amines; Antiviral Agents; Common Cold; Guanidines; Humans; Influenza, Human; Intercellul | 1999 |
Pleconaril. A broad spectrum antipicornaviral agent.
Topics: Antiviral Agents; Enterovirus; Humans; Meningitis, Viral; Oxadiazoles; Oxazoles; Picornaviridae Infe | 1999 |
[Pleconaril, a new aniviral drug with activity against picornavirus].
Topics: Animals; Antiviral Agents; Drug Resistance; Humans; Oxadiazoles; Oxazoles; Picornaviridae; Picornavi | 2000 |
The treatment of rhinovirus infections: progress and potential.
Topics: 3C Viral Proteases; Antiviral Agents; Clinical Trials as Topic; Combined Modality Therapy; Common Co | 2001 |
Pleconaril Sanofi Synthélabo/ViroPharma.
Topics: Antiviral Agents; Clinical Trials as Topic; Contraindications; Drugs, Investigational; Humans; Oxadi | 2000 |
2 trials available for pleconaril and Infections, Picornaviridae
| Article | Year |
|---|---|
Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials.
Topics: Administration, Oral; Adult; Antiviral Agents; Common Cold; Diarrhea; Double-Blind Method; Female; H | 2003 |
Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Double-Blind Met | 2002 |
7 other studies available for pleconaril and Infections, Picornaviridae
| Article | Year |
|---|---|
Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders.
Topics: Animals; Antiviral Agents; Capsid; Capsid Proteins; Humans; Microsomes; Picornaviridae Infections; P | 2011 |
Cryo-EM structure of pleconaril-resistant rhinovirus-B5 complexed to the antiviral OBR-5-340 reveals unexpected binding site.
Topics: Antiviral Agents; Binding Sites; Capsid; Cryoelectron Microscopy; Drug Resistance, Viral; HeLa Cells | 2019 |
Antiviral treatments reduce severity of diabetes in Ljungan virus-infected CD-1 mice and delay onset in diabetes-prone BB rats.
Topics: Animals; Antibodies, Viral; Antiviral Agents; Diabetes Mellitus, Type 1; Drug Therapy, Combination; | 2009 |
Anti-human rhinovirus activity of raoulic acid from Raoulia australis.
Topics: Antiviral Agents; Asteraceae; Common Cold; Humans; Microbial Sensitivity Tests; Oxadiazoles; Oxazole | 2010 |
Pleconaril-resistant chronic parechovirus-associated enteropathy in agammaglobulinaemia.
Topics: Adolescent; Agammaglobulinemia; Antiviral Agents; Caliciviridae Infections; Chronic Disease; Drug Re | 2011 |
Safety and efficacy evaluation of pleconaril for treatment of the common cold.
Topics: Adult; Antiviral Agents; Common Cold; Controlled Clinical Trials as Topic; Drug Resistance, Viral; E | 2003 |
[New antivirals for respiratory tract viruses].
Topics: Antiviral Agents; Drug Approval; France; Guanidines; Humans; Influenza, Human; Neuraminidase; Oxadia | 1999 |